Drugs Stocks On The Rise With Help From 3 Stocks

Editor's Note: Any reference to TheStreet Ratings and its underlying recommendation does not reflect the opinion of TheStreet, Inc. or any of its contributors including Jim Cramer or Stephanie Link.

One out of the three major indices are trading lower today with the Dow Jones Industrial Average ( ^DJI) trading up 5 points (0.0%) at 16,485 as of Friday, Dec. 27, 2013, 11:55 AM ET. The NYSE advances/declines ratio sits at 1,370 issues advancing vs. 1,569 declining with 149 unchanged.

The Drugs industry currently sits down 0.7% versus the S&P 500, which is unchanged. Top gainers within the industry include Shire ( SHPG), up 1.2%, GlaxoSmithKline ( GSK), up 1.0%, Novo Nordisk A/S ( NVO), up 0.8%, Amgen ( AMGN), up 0.6% and Celgene Corporation ( CELG), up 0.5%.

TheStreet would like to highlight 3 stocks pushing the industry higher today:

3. Sanofi ( SNY) is one of the companies pushing the Drugs industry higher today. As of noon trading, Sanofi is up $0.48 (0.9%) to $52.72 on light volume. Thus far, 304,731 shares of Sanofi exchanged hands as compared to its average daily volume of 1.1 million shares. The stock has ranged in price between $52.48-$52.92 after having opened the day at $52.63 as compared to the previous trading day's close of $52.24.

Sanofi researches, develops, manufactures, and markets healthcare products worldwide. The company operates through Pharmaceuticals, Human Vaccines, and Animal Health segments. Sanofi has a market cap of $137.7 billion and is part of the health care sector. Shares are up 10.3% year to date as of the close of trading on Thursday. Currently there are 2 analysts that rate Sanofi a buy, no analysts rate it a sell, and 3 rate it a hold.

TheStreet Ratings rates Sanofi as a buy. The company's strengths can be seen in multiple areas, such as its revenue growth, expanding profit margins and increase in stock price during the past year. We feel these strengths outweigh the fact that the company has had sub par growth in net income. Get the full Sanofi Ratings Report now.

3x UPSIDE POTENTIAL: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12-months. Learn more.

2. As of noon trading, Novartis ( NVS) is up $1.45 (1.8%) to $80.41 on light volume. Thus far, 478,896 shares of Novartis exchanged hands as compared to its average daily volume of 1.3 million shares. The stock has ranged in price between $80.03-$80.55 after having opened the day at $80.25 as compared to the previous trading day's close of $78.96.

Novartis AG engages in the research, development, manufacture, and marketing of a range of healthcare products worldwide. Novartis has a market cap of $191.8 billion and is part of the health care sector. Shares are up 24.7% year to date as of the close of trading on Thursday. Currently there are 5 analysts that rate Novartis a buy, no analysts rate it a sell, and 4 rate it a hold.

TheStreet Ratings rates Novartis as a buy. The company's strengths can be seen in multiple areas, such as its revenue growth, reasonable valuation levels, good cash flow from operations, largely solid financial position with reasonable debt levels by most measures and increase in stock price during the past year. We feel these strengths outweigh the fact that the company has had sub par growth in net income. Get the full Novartis Ratings Report now.

3x UPSIDE POTENTIAL: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12-months. Learn more.

1. As of noon trading, AstraZeneca ( AZN) is up $0.31 (0.5%) to $59.42 on light volume. Thus far, 515,900 shares of AstraZeneca exchanged hands as compared to its average daily volume of 1.8 million shares. The stock has ranged in price between $59.23-$59.49 after having opened the day at $59.40 as compared to the previous trading day's close of $59.11.

AstraZeneca PLC engages in the discovery, development, and commercialization of prescription medicines for cardiovascular, gastrointestinal, neuroscience, infection, oncology, and respiratory and inflammation diseases worldwide. AstraZeneca has a market cap of $73.7 billion and is part of the health care sector. Shares are up 25.1% year to date as of the close of trading on Thursday. Currently there are no analysts that rate AstraZeneca a buy, 1 analyst rates it a sell, and 5 rate it a hold.

TheStreet Ratings rates AstraZeneca as a buy. The company's strengths can be seen in multiple areas, such as its largely solid financial position with reasonable debt levels by most measures, attractive valuation levels, increase in stock price during the past year and expanding profit margins. We feel these strengths outweigh the fact that the company has had sub par growth in net income. Get the full AstraZeneca Ratings Report now.

3x UPSIDE POTENTIAL: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12-months. Learn more.

If you are interested in one of these 3 stocks, ETFs may be of interest. Investors who are bullish on the drugs industry could consider SPDR S&P Pharmaceuticals ETF ( XPH) while those bearish on the drugs industry could consider ProShares UltraShort Nasdaq Biotech ( BIS).

null

More from Markets

Stocks Rise as Bond Yields Inch Closer to 3% Threshold

Stocks Rise as Bond Yields Inch Closer to 3% Threshold

Akorn's Stock Crashes as Germany's Fresenius Ends Takeover Amid Data Allegations

Akorn's Stock Crashes as Germany's Fresenius Ends Takeover Amid Data Allegations

Trump to Blame for Oil's Recent Surge, Not OPEC

Trump to Blame for Oil's Recent Surge, Not OPEC

3 Things Investors Must Know for Monday

3 Things Investors Must Know for Monday

U.S. Earnings On Pace for Best Season in Two Decades but Tech Giants Await

U.S. Earnings On Pace for Best Season in Two Decades but Tech Giants Await